Targets › RRM1
16 programs from 15 companies in 63 trials: 37 Phase 2, 19 Phase 1, 5 Phase 3, 2 Phase 4; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Part of the ribonucleotide reductase (RNR) complex composed of a catalytic large alpha subunit (RRM1/RR1) and a small beta subunit, either RRM2/RR2 or RRM2B/RR2B required for DNA synthesis. The active form is an alpha2beta2 heterotetramer in which the RR1-containing subunits (alpha2) catalyze reduction of ribonucleotides to deoxyribonucleotides, while the RRM2-containing subunits (beta2) provide the diferric-tyrosyl…. (UniProt, P23921)
Open in Phaseline: the race on RRM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangsu Healthy Life Innovation Medical Technology | Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 3 | Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor … | Dec 2026 |
| First Affiliated Hospital, Sun Yat-Sen University | Induction Chemotherapy (TPF regimen) Docetaxel, cisplatin, and 5-fluorouracil combination | Tubulin, TP53, TYMS, RRM1 | Phase 3 | Locally Advanced Nasopharyngeal Carcinoma | Aug 2027 |
| InnoPharmax | D07001-Softgel Capsules Gemcitabine, a nucleoside analog | RRM1, RRM2 | Phase 3 | Biliary Tract Cancer (BTC); Biliary Tract Cancer | Dec 2028 |
| Memorial Sloan Kettering Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | AML | Dec 2026 |
| Dana-Farber Cancer Institute | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis | Dec 2026 |
| Peking Union Medical College Hospital | GC Combination of gemcitabine and cisplatin | RRM1, RRM2, DCK, ERCC1 | Phase 2 | Biliary Tract Neoplasms Immunotherapy | Jan 2027 |
| M.D. Anderson Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Recurrent Acute Lymphoblastic Leukemia | Aug 2027 |
| City of Hope Medical Center | clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Adult Acute Lymphoblastic Leukemia in Remission | Aug 2027 |
| Theravia | Hydroxyurea Ribonucleoside-diphosphate reductase RR1 inhibitor | RRM1, RRM2B, RRM2 | Phase 2 | Sickle Cell Disease; Sickle Cell Anemia (HbSS); Sickle Cell Anemia in Children; Primary Immunodeficiency (PID) … | Feb 2028 |
| West China Second University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis (LCH) | Jun 2028 |
| Nantes University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Acute Myeloid Leukemia in Remission | Sep 2028 |
| Princess Maxima Center for Pediatric Oncology | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Relapsed Pediatric AML | Dec 2026 |
| City of Hope Medical Center | COH29 Ribonucleotide reductase (RNR) inhibitor | RRM1, RRM2 | Phase 1 | Unspecified Adult Solid Tumor, Protocol Specific | May 2027 |
| Jiangsu Hansoh Pharmaceutical | HS-10566 Intravesical gemcitabine delivery system | RRM1, RRM2, DCK | Phase 1 | High-risk Non-muscle-invasive Bladder Cancer | Apr 2028 |
| Ekaterina Laukhtina | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Advanced Urothelial Carcinoma | Nov 2028 |
| Beijing Immunochina Medical Science & Technology | Fludarabine Phosphate (IM19) Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia … | Jun 2035 |
Sickle Cell Disease (7) Sickle Cell Anemia in Children (2) Metabolic Disorders (2) Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) Sickle Cell Anemia (HbSS) (1) Primary Immunodeficiency (PID) (1) Sickle Cell Disease (SCD) (1)
small molecule (10), mixed (2), protein or peptide (2), other (1)
City of Hope Medical Center (2) M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Theravia (1) First Affiliated Hospital, Sun Yat-Sen University (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) Memorial Sloan Kettering Cancer Center (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) InnoPharmax (1) Jiangsu Hansoh Pharmaceutical (1) Princess Maxima Center for Pediatric Oncology (1) Peking Union Medical College Hospital (1)
RRM2 (15) RRM2B (11) POLA1 (10) POLD4 (10) DCK (2) Tubulin (1) TP53 (1) TYMS (1) ERCC1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.